High Circulating IL-6 Level in Graves' Ophthalmopathy

References

• Bartalena L., Brogioni S., Grasso L., Rago T., Vitti P., Pinchera A., et al. Interleukin-6: Marker of thyroid-destructive processes?. J. Clin. Endocrinol. Metab. 1994; 19: 1424–1427
   Google Scholar
• Zheng R. Q. H., Abney E., Chu C. Q., Field M., Grubeck-Loebenstein B., Maini R. N., et al. Detection of interleukin-6 and interleukin-1 production in human thyroid epithelial cells by non-radioactive in situ hybridization and immunohistochemical methods. Clin. Exp. Immunol. 1991; 83: 314–319
   PubMedGoogle Scholar
• Paschke R., Schuppert F., Taton M., Velu T. Intrathyroidal cytokine gene expression profiles in autoimmune thyroiditis. J. Endocrinol. 1994; 141: 309–315
   PubMed Web of Science ®Google Scholar
• Watson P. F., Pickerill A. P., Davies R., Weetman A. P. Analysis of cytokine gene expression in Graves' disease and multinodular goiter. J. Clin. Endocrinol, Metab. 1994; 79: 355–3605
   PubMed Web of Science ®Google Scholar
• Weetman A. P. Thyroid-associated eye disease: pathophysiology. Lancet 1991; ii: 25–28
   Google Scholar
• Bahn R. S., Heufelder A. E. Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy. Thyroid 1992; 2: 89–93
   PubMed Web of Science ®Google Scholar
• Grubeck-Loebenstein B., Trieb K., Sztankay A., Holter W., Anderl H., Wick G. Retrobulbar T cell from patients with Graves' ophthalmopathy are CD8+ an specifically recognize autologuos fibroblasts. J. Clin. Invest. 1994; 93: 2738–2743
   PubMed Web of Science ®Google Scholar
• Werner S. C. Modification of classification of eye changes of Graves' disease: recommendations of the Ad Hoc Committee of American Thyroid Association. J. Clin. Endocrinol. Metab. 1977; 44: 203
   PubMed Web of Science ®Google Scholar
• Voller A., Bartlett A., Bidwell D. E. Enzyme immunoassays with special reference to ELISA techniques. J. Clin. Pathol. 1978; 31: 507–520
   PubMed Web of Science ®Google Scholar
• Molnar I., Balazs C., Szabó E., Czirják L. Evaluation of thyroid function and anti-thyroid autoantibodies in systemic sclerosis. Acta Derm. Venereol. (Stockh) 1991; 72: 112–114
   Google Scholar
• Hamada N., Grimm C., Mori H., Degroot L. J. Identification of a thyroid microsomal antigen by Western blot and immuno-precipitation. J. Clin. Endocrinol. Metab. 1985; 61: 1201–28
   Google Scholar
• Taurog A., Lothrop M. L., Estabrook R. W. Improvements in the isolation procedure for thyroid peroxidase: nature of the heme prosthetic group. Arch Biochem. Biophys. 1970; 12: 221–224
   Google Scholar
• Kuhweide R., Van Damme J., Ceuppens J. L. Tumor necrosis factor-a and interleukin 6 synergistically induced T cell growth. Eur. J. Immunol. 1990; 20: 1019–1025
   Google Scholar
• Nakamura T., Ebihara I., Takahashi T., Yamamoto M., Tomino Y., Koide H. Increased interleukin 6 mRNA expression by peripheral blood T cells from patients with IgA nephropathy. Autoimmunity 1993; 15: 171–179
   PubMed Web of Science ®Google Scholar
• Jones T. H. Interleukin-6 an endocrine cytokine. Clin. Endocrinol. 1994; 40: 703–713
   PubMedGoogle Scholar
• Luger T. A., Schwarz T. The role of cytokines and neuroendocrine hormones in cutaneous immunity and inflammation. Allergy 1995; 50: 292–302
   Google Scholar
• Weetman A. P., Bright-Thimas R., Freeman M. Regulation ofinterleukin-6 release by human thyrocytes. J. Endocrinol. 1990; 127: 357–361
   PubMed Web of Science ®Google Scholar
• Balazs C. Increased level of soluble interleukin-2 receptor in sera of patients with Graves' disease. Biomed. Pharmacother. 1991; 45: 311–314
   Google Scholar
• van Haasteren G. A. C., van der Meer M. J. M., Hermus A. R. M. M., Linkels E., Klootwijk W., Kaptein E., et al. Different effects of continuous infusion of interleukin-1 and interleukin-6 on the hypothalamic-hypophysial-thyroid axis. Endocrinology 1994; 135: 1336–1345
   Google Scholar
• Wolf M., Hansen N., Greten H. Interleukin ID, tumor necrosis factor-a and interleukin 6 decrease nuclear thyroid hormone receptor capacity in a liver cell line. Eur. J. Endocrinol. 1994; 131: 307–312
   Google Scholar
• Bartalena L., Grasso L., Brogioni S., Aghini-Lombardi F., Braverman L. E., Martino E. Serum interleukin-6 in Amiodarone-induced thyrotoxicosis. J. Clin. Endocrinol. Metab. 1994; 87: 423–426
   Google Scholar
• Mooij P., Simons P. J., de Haan-Meulman M., de Wit H. J., Drexhage H. A. Effect of thyroid hormones and other iodinated compounds on the transition of monocytes into veiled/dendritic cells: role of granulocyte-macrophage colony-stimulating factor, tumour-necrosis factor-a and interleukin-6. J. Endocrinol. 1994; 140: 503–512
   Google Scholar
• Ramsay A. J., Husband A. J., Ramshaw I. A., Bao S., Matthaei K. I., Koehler G., et al. The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264: 561–563
   PubMed Web of Science ®Google Scholar
• Molnar I., Kaczur V., Boros A, Krajczár G., Balazs C. IgA autoantibodies against human eye muscle antigen detected by western blotting and immunohistochemical methods in Graves' disease. J. Endocrinol. Invest. 1995; 18: 408–414
   PubMedGoogle Scholar
• Oen K., Danell G. Interleukin 6 and autoantibodies in juvenile rheumatoid arthritis. J. Rheumatol. 1993; 20: 1949–1956
   PubMed Web of Science ®Google Scholar
• Klein B., Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunology Today 1995; 16: 216–220
   PubMedGoogle Scholar